The mouse C1q A-chain sequence alters beta-amyloid-induced complement activation

Neurobiology of Aging

Volumn 20, Issue 3, 1999, Pages 297-304

  Webster, S D ^a   Tenner, A J ^a   Poulos, T L ^a   Cribbs, D H ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Beta amyloid; C1q; Complement activation; Neurodegeneration; Neuroinflammation; Transgenic

Indexed keywords

AMYLOID BETA PROTEIN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C4;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; ENCEPHALITIS; HUMAN; MOUSE; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; TRANSGENIC ANIMAL;

EID: 0033133360     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(99)00020-2     Document Type: Article

References (45)

1. Afagh A., Cummings B.J., Cribbs D.H., Cotman C.W., Tenner A.J. Localization and cell association of C1q in Alzheimer's disease brain. Exp Neurol. 138:1996;22-32.
2. Aisen P.S. Inflammation, and Alzheimer's disease mechanisms and therapeutic strategies . Gerontology. 43:1997;143-149.
3. Atkinson J.P., McGinnis K., Shreffler D. Development and characterization of a hemolytic assay for mouse C4. J Immunol Methods. 33:1980;351-368.
4. SW transgenic mice. Soc Neurosci Abst. 28:1998;1503.
5. Borchelt D.R., Ratovitski T., van Lare J., et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron. 19:1997;939-945.
6. Bradt B.M., Kolb W.P., Cooper N.R. Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J Exp Med. 188:1998;431-438.
7. Breitner J.C. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu Rev Med. 47:1996;401-411.
8. Burdick D., Soreghan B., Kwon M., et al. Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J Biol Chem. 267:1992;546-554.
9. Cooper N.R. The classical complement pathway activation and regulation of the first complement component . Adv Immunol. 37:1985;151-216.
10. Cotman C.W., Tenner A.J., Cummings B.J. Beta-amyloid converts an acute phase injury response to chronic injury responses. Neurobiol Aging. 17:1996;723-731.
11. Cribbs D.H., Velazquez P., Soreghan B., Glabe C.G., Tenner A.J. Complement activation by cross-linked truncated and chimeric full-length beta-amyloid. Neuroreport. 8:1997;3457-3462.
12. Ebanks R.O., Isenman D.E. Mouse complement component C4 is devoid of classical pathway C5 convertase subunit activity. Mol Immunol. 33:1996;297-309.
13. Eikelenboom P., Hack C.E., Rozemuller J.M., Stam F.C. Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch B Cell Pathol Incl Mol Pathol. 56:1989;259-262.
14. Eikelenboom P., Zhan S.S., van Gool W.A., Allsop D. Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol Sci. 15:1994;447-450.
15. Eikelenboom P., Veerhuis R. The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Neurobiol Aging. 17:1996;673-680.
16. Games D., Adams D., Alessandrini R., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 373:1995;523-527.
17. Gewurz H., Ying S.C., Jiang H., Lint T.F. Nonimmune activation of the classical complement pathway. Behring Inst Mitt. 1993;138-147.
18. Grenfell T.H., Mori C., Stoltzner S., et al. Accrual of Aβ-associated proteins in plaques in the PD-APP transgenic mouse brain. Soc Neurosci Abst. 28:1998;729.
19. Harlow E., Lane D. Antibodies A laboratory manual . 1988;Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
20. Holcomb L., Gordon M.N., McGowan E., et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med. 4:1998;97-100.
21. Hsiao K., Chapman P., Nilsen S., et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science. 274:1996;99-102.
22. Jiang H.X., Siegel J.N., Gewurz H. Binding and complement activation by C-reactive protein via the collagen-like region of C1q and inhibition of these reactions by monoclonal antibodies to C-reactive protein and C1q. J Immunol. 146:1991;2324-2330.
23. Jiang H., Cooper B., Robey F.A., Gewurz H. DNA binds and activates complement via residues 14-26 of the human C1q A chain. J Biol Chem. 267:1992;25597-25601.
24. Jiang H., Robey F.A., Gewurz H. Localization of sites through which C-reactive protein binds and activates complement to residues 14-26 and 76-92 of the human C1q A chain. J Exp Med. 175:1992;1373-1379.
25. Jiang H., Burdick D., Glabe C.G., Cotman C.W., Tenner A.J. Beta-amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J Immunol. 152:1994;5050-5059.
26. Kilchherr E., Hofmann H., Steigemann W., Engel J. Structural model of the collagen-like region of C1q comprising the kink region and the fibre-like packing of the six triple helices. J Mol Biol. 186:1985;403-415.
27. Mackenzie I.R., Munoz D.G. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology. 50:1998;986-990.
28. McGeer P.L., Akiyama H., Itagaki S., McGeer E.G. Immune system response in Alzheimer's disease. Can J Neurol Sci. 16:1989;516-527.
29. McGeer P.L., Schulzer M., McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease a review of 17 epidemiologic studies . Neurology. 47:1996;425-432.
30. O'Banion M.K., Finch C.E. Inflammatory mechanisms and anti-inflammatory therapy in Alzheimer's disease. Neurobiol Aging. 17:1996;669-671.
31. Ong G.L., Mattes M.J. Mouse strains with typical mammalian levels of complement activity. J Immunol Methods. 125:1989;147-158.
32. Oyama F., Sawamura N., Kobayashi K., et al. Mutant presenilin 2 transgenic mouse effect on an age-dependent increase of amyloid beta-protein 42 in the brain . J Neurochem. 71:1998;313-322.
33. Pasinetti G.M. Inflammatory mechanisms in neurodegeneration and Alzheimer's disease the role of the complement system . Neurobiol Aging. 17:1996;707-716.
34. Rogers J., Cooper N.R., Webster S., et al. Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci USA. 89:1992;10016-10020.
35. Schauwecker P.E., Steward O. Genetic determinants of susceptibility to excitotoxic cell death implications for gene targeting approaches . Proc Natl Acad Sci USA. 94:1997;4103-4108.
36. Small G.W. Treatment of Alzheimer's disease current approaches and promising developments . Am J Med. 104:1998;32S-38S.
37. Szalai A.J., Briles D.E., Volanakis J.E. Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in transgenic mice. J Immunol. 155:1995;2557-2563.
38. Velazquez P., Cribbs D.H., Poulos T.L., Tenner A.J. Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation implications for Alzheimer's disease pathogenesis . Nat Med. 3:1997;77-79.
39. Webster S., Glabe C., Rogers J. Multivalent binding of complement protein C1q to the amyloid beta-peptide (A beta) promotes the nucleation phase of A beta aggregation. Biochem Biophys Res Commun. 217:1995;869-875.
40. Webster S., Bradt B., Rogers J., Cooper N. Aggregation state-dependent activation of the classical complement pathway by the amyloid β-peptide. J Neurochem. 69:1997;388-398.
41. Webster S., Lue L.-F., Brachova L., et al. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol Aging. 18:1997;415-421.
42. Whaley K., North J. Haemolytic assays for whole complement activity and individual components. Dodds A., Sim R. Complement a practical approach . 1997;19-47 IRL Press, Oxford, England.
43. Ying S.C., Gewurz A.T., Jiang H., Gewurz H. Human serum amyloid P component oligomers bind and activate the classical complement pathway via residues 14-26 and 76-92 of the A chain collagen-like region of C1q. J Immunol. 150:1993;169-176.
44. Yu J.X., Bradt B.M., Hsiao K., Cooper N.R. The third complement component is associated with amyloid plaques in human APP695SWE transgenic mice. Soc Neurosci Abst. 28:1998;730.
45. Zahedi K., Whitehead A.S. Regulation of mouse serum amyloid P gene expression by cytokines in vitro. Biochim Biophys Acta. 1176:1993;162-168.